PD 166326

ABL proto-oncogene 1, non-receptor tyrosine kinase ; Homo sapiens







8 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 19567819 Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. 2009 Jul 1
2 17043649 Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. 2007 Apr 12 3
3 17929114 The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. 2007 Oct 1
4 17076652 New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. 2006 Oct 1
5 15459011 A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. 2005 Feb 15 2
6 15273685 Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation. 2004 Aug 1
7 12684394 A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. 2003 Apr 5
8 12154026 Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. 2002 Aug 1 1